Li, Jie <br/><br/>
Loganetin protects against rhabdomyolysis-induced acute kidney injury by modulating the toll-like receptor 4 signalling pathway.  [electronic resource] 

 -  British journal of pharmacology  04 2019 
 - 1106-1121 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5381 
<br/><br/><label>Standard No.: </label>10.1111/bph.14595  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acute Kidney Injury--drug therapy<br/>Animals<br/>Cell Line<br/>Humans<br/>Kidney--drug effects<br/>MAP Kinase Signaling System--drug effects<br/>Male<br/>Mice, Inbred C57BL<br/>Mice, Knockout<br/>NF-kappa B--metabolism<br/>Protective Agents--pharmacology<br/>Rhabdomyolysis--complications<br/>Signal Transduction<br/>Toll-Like Receptor 4--antagonists & inhibitors